Stock Analysis

TotalEnergies SE (EPA:TTE) Analysts Just Slashed This Year's Revenue Estimates By 11%

ENXTPA:TTE
Source: Shutterstock

The analysts covering TotalEnergies SE (EPA:TTE) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the 20 analysts covering TotalEnergies provided consensus estimates of US$191b revenue in 2025, which would reflect a noticeable 2.1% decline on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$214b in 2025. The consensus view seems to have become more pessimistic on TotalEnergies, noting the measurable cut to revenue estimates in this update.

View our latest analysis for TotalEnergies

earnings-and-revenue-growth
ENXTPA:TTE Earnings and Revenue Growth February 14th 2025

There was no particular change to the consensus price target of US$71.87, with TotalEnergies' latest outlook seemingly not enough to result in a change of valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic TotalEnergies analyst has a price target of US$93.76 per share, while the most pessimistic values it at US$62.25. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 2.1% by the end of 2025. This indicates a significant reduction from annual growth of 9.6% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 2.5% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - TotalEnergies is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on TotalEnergies after today.

Of course, this isn't the full story. We have estimates for TotalEnergies from its 20 analysts out until 2027, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Valuation is complex, but we're here to simplify it.

Discover if TotalEnergies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:TTE

TotalEnergies

A multi-energy company, produces and markets oil and biofuels, natural gas, green gases, renewables, and electricity in France, rest of Europe, North America, Africa, and internationally.

Flawless balance sheet established dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|36.403% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|25.014999999999997% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.1226% overvalued
Jonataninho
Jonataninho
Community Contributor